CANTERBURY DHB (HAEMATOLOGY DEPARTMENT)

PAGE 1 OF 1

AML 15 – Consolidation – ARA C 1.5 / DELIVER TO: HDWBMTU
Patient Category:
Y J A P O 1 3 Z / OSP Group:
1 2 3 4 5 6 7 / Doctors Name:
NZMC Reg. No.: / Special Authority Number:
Antiemetics
Metoclopramide PO/IV 20mg QID
± Cyclizine 50mg PO/IV TDS
± Ondansetron 8mg PO BD PRN / Weight kg / Height cm
BSA m2
Dose Modified / NoYes
Cycle: Ensure neutrophils are more than 1.0 X 109/L and platelets are more than 100 X 109/L before commencing cycle 4 / ADMINISTRATION USE
DAY / DATE / TIME / CHEMOTHERAPY AGENT /

DOSE

/

ROUTE

/ INSTRUCTIONS / DR SIGN / GIVEN BY / CHECK / TIME
1 / T=0hr / Cytarabine 1500mg/m2 / mg / IV / In 1L 0.9S over 4 hours
T+12hr / Cytarabine 1500mg/m2 / mg / IV / In 1L 0.9S over 4 hours
3 / T=0hr / Cytarabine 1500mg/m2 / mg / IV / In 1L 0.9S over 4 hours
T+12hr / Cytarabine 1500mg/m2 / mg / IV / In 1L 0.9S over 4 hours
5 / T=0hr / Cytarabine 1500mg/m2 / mg / IV / In 1L 0.9S over 4 hours
T+12hr / Cytarabine 1500mg/m2 / mg / IV / In 1L 0.9S over 4 hours

Chemotherapy rounding: Cytarabine> 1000mg 100mg

Note: Chart Prednisolone eyedrops 1% TDS starting 12 hours before cytarabine and continue for 5 days after completion. Chart on QMR4

If randomised to consolidation cycle 5 (only patients 45yrs can be randomised), ensure neutrophils are more than1 X 109/L and

platelets more than 80 X 109/L before beginning cycle 5.

Authorised by Clinical Director: S Gibbons Pharmacist: B Harden / 20 November 2007
G:\Division\HAE\CLIN\USER\Jen\Chemo charts\AML\AML 15 - Consolidation - ARA C 1.5.doc / Ref: 2000
CHEMOTHERAPY
MEDICATION
CHART
C
260070